PL3692023T3 - Związki benzotiazolowe i sposoby ich stosowania w leczeniu zaburzeń neurodegeneracyjnych - Google Patents
Związki benzotiazolowe i sposoby ich stosowania w leczeniu zaburzeń neurodegeneracyjnychInfo
- Publication number
- PL3692023T3 PL3692023T3 PL18864678.0T PL18864678T PL3692023T3 PL 3692023 T3 PL3692023 T3 PL 3692023T3 PL 18864678 T PL18864678 T PL 18864678T PL 3692023 T3 PL3692023 T3 PL 3692023T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- same
- neurodegenerative disorders
- treating neurodegenerative
- benzothiazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566649P | 2017-10-02 | 2017-10-02 | |
| US201862666800P | 2018-05-04 | 2018-05-04 | |
| US201862696432P | 2018-07-11 | 2018-07-11 | |
| PCT/KR2018/011660 WO2019070093A1 (en) | 2017-10-02 | 2018-10-01 | BENZOTHIAZOL COMPOUNDS AND METHODS OF USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3692023T3 true PL3692023T3 (pl) | 2023-12-11 |
Family
ID=65897719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18864678.0T PL3692023T3 (pl) | 2017-10-02 | 2018-10-01 | Związki benzotiazolowe i sposoby ich stosowania w leczeniu zaburzeń neurodegeneracyjnych |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10669246B2 (pl) |
| EP (1) | EP3692023B1 (pl) |
| JP (2) | JP2020536116A (pl) |
| KR (1) | KR102858188B1 (pl) |
| CN (1) | CN111315727B (pl) |
| AU (1) | AU2018346051B2 (pl) |
| CA (1) | CA3078173A1 (pl) |
| ES (1) | ES2953025T3 (pl) |
| FI (1) | FI3692023T3 (pl) |
| HU (1) | HUE062526T2 (pl) |
| IL (1) | IL273705B2 (pl) |
| MX (1) | MX2020003593A (pl) |
| PL (1) | PL3692023T3 (pl) |
| PT (1) | PT3692023T (pl) |
| WO (1) | WO2019070093A1 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2953025T3 (es) | 2017-10-02 | 2023-11-07 | 1St Biotherapeutics Inc | Compuestos de benzotiazol y métodos que usan los mismos para tratar trastornos neurodegenerativos |
| MX2021010122A (es) | 2019-02-22 | 2021-09-23 | 1St Biotherapeutics Inc | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. |
| US20220160902A1 (en) * | 2019-03-07 | 2022-05-26 | 1ST Biotherapeutics, Inc. | [18F]-Labeled Benzothiazole Derivative As PET Radiotracer |
| US10385046B1 (en) * | 2019-03-19 | 2019-08-20 | 1ST Biotherapeutics, Inc. | Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders |
| CN113631554B (zh) * | 2019-03-28 | 2024-06-21 | 第一生物治疗股份有限公司 | 苯并噻唑化合物的药用盐、多晶型物及其制备方法 |
| CN110483402B (zh) * | 2019-08-12 | 2021-07-23 | 上海毕得医药科技股份有限公司 | 一种3-溴-5-苯基-1h-吡唑的合成方法 |
| US12398156B2 (en) | 2020-08-21 | 2025-08-26 | 1ST Biotherapeutics, Inc. | Compounds for prevention or treatment of neurodegenerative disorders |
| JP7773233B2 (ja) * | 2020-08-21 | 2025-11-19 | ファースト・バイオセラピューティクス・インコーポレイテッド | Pet放射性トレーサとしての[18f]標識イミダゾピリジン誘導体 |
| TWI908894B (zh) | 2020-09-28 | 2025-12-21 | 南韓商福斯特生物股份有限公司 | 作為造血前驅細胞激酶1(hpk1)抑制劑的吲唑及其用途 |
| ES3036969T3 (en) | 2020-09-30 | 2025-09-25 | Asahi Kasei Pharma Corp | Nitrogen-containing bicyclic compounds which contain pyrimidine as interleukin 1 receptor-associated kinase 4 (irak-4) inhibitors to be used in the treatment of inflammatory or autoimmune diseases |
| TWI898106B (zh) * | 2022-01-11 | 2025-09-21 | 日商旭化成製藥股份有限公司 | 含有嘧啶之含氮雙環化合物 |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| CN117551038A (zh) * | 2023-07-25 | 2024-02-13 | 上海毕得医药科技股份有限公司 | 一种硼酸促进4-溴-7-甲基-1h-吲唑关环制备的合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1187453A (en) * | 1915-09-20 | 1916-06-13 | Allis Chalmers Mfg Co | Steam-turbine. |
| US2258671A (en) * | 1940-01-27 | 1941-10-14 | Nat Oil Prod Co | Refining of fat-soluble vitamincontaining materials |
| CA2309319A1 (en) * | 1997-11-10 | 1999-05-20 | Bristol-Myers Squibb Company | Benzothiazole protein tyrosine kinase inhibitors |
| WO2001057008A1 (en) * | 2000-02-07 | 2001-08-09 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| CN101384586A (zh) * | 2006-02-14 | 2009-03-11 | 诺华公司 | Pi-3激酶抑制剂及其应用方法 |
| PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| US20100029619A1 (en) | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
| EP2178868A1 (en) | 2007-07-18 | 2010-04-28 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| US7928140B2 (en) | 2007-08-02 | 2011-04-19 | Amgen Inc. | Benzothiazole PI3 kinase modulators for cancer treatment |
| US8993580B2 (en) * | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| AR071523A1 (es) | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
| EP2311842A3 (en) | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
| AU2009268611B2 (en) * | 2008-07-08 | 2015-04-09 | Intellikine, Llc | Kinase inhibitors and methods of use |
| JP4528849B2 (ja) * | 2008-07-14 | 2010-08-25 | シャープ株式会社 | 引出し型加熱調理器 |
| WO2010100144A1 (en) * | 2009-03-04 | 2010-09-10 | Merck Serono S.A. | Fused bicyclic compounds as inhibitors for pi3 kinase |
| EP2440058A4 (en) | 2009-06-12 | 2012-11-21 | Dana Farber Cancer Inst Inc | MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| TW201307292A (zh) * | 2010-12-17 | 2013-02-16 | Hoffmann La Roche | 經取代之6,6-稠合含氮雜環化合物及其用途 |
| KR20140107153A (ko) | 2014-07-23 | 2014-09-04 | 한국과학기술원 | 인돌 유도체 화합물, 이를 포함하는 Abl 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물 |
| ES2953025T3 (es) | 2017-10-02 | 2023-11-07 | 1St Biotherapeutics Inc | Compuestos de benzotiazol y métodos que usan los mismos para tratar trastornos neurodegenerativos |
-
2018
- 2018-10-01 ES ES18864678T patent/ES2953025T3/es active Active
- 2018-10-01 JP JP2020520037A patent/JP2020536116A/ja active Pending
- 2018-10-01 CN CN201880063869.7A patent/CN111315727B/zh active Active
- 2018-10-01 FI FIEP18864678.0T patent/FI3692023T3/fi active
- 2018-10-01 AU AU2018346051A patent/AU2018346051B2/en active Active
- 2018-10-01 PL PL18864678.0T patent/PL3692023T3/pl unknown
- 2018-10-01 HU HUE18864678A patent/HUE062526T2/hu unknown
- 2018-10-01 CA CA3078173A patent/CA3078173A1/en active Pending
- 2018-10-01 WO PCT/KR2018/011660 patent/WO2019070093A1/en not_active Ceased
- 2018-10-01 US US16/148,265 patent/US10669246B2/en active Active
- 2018-10-01 EP EP18864678.0A patent/EP3692023B1/en active Active
- 2018-10-01 PT PT188646780T patent/PT3692023T/pt unknown
- 2018-10-01 MX MX2020003593A patent/MX2020003593A/es unknown
- 2018-10-01 KR KR1020207012653A patent/KR102858188B1/ko active Active
-
2020
- 2020-03-30 IL IL273705A patent/IL273705B2/en unknown
- 2020-05-14 US US15/931,827 patent/US10968188B2/en active Active
-
2023
- 2023-05-15 JP JP2023080175A patent/JP7605898B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE062526T2 (hu) | 2023-11-28 |
| IL273705B2 (en) | 2023-02-01 |
| CN111315727A (zh) | 2020-06-19 |
| US20190100500A1 (en) | 2019-04-04 |
| US10968188B2 (en) | 2021-04-06 |
| IL273705B (en) | 2022-10-01 |
| MX2020003593A (es) | 2020-07-22 |
| KR20200051832A (ko) | 2020-05-13 |
| CN111315727B (zh) | 2023-09-29 |
| WO2019070093A1 (en) | 2019-04-11 |
| US10669246B2 (en) | 2020-06-02 |
| CA3078173A1 (en) | 2019-04-11 |
| ES2953025T3 (es) | 2023-11-07 |
| EP3692023A1 (en) | 2020-08-12 |
| EP3692023B1 (en) | 2023-05-17 |
| IL273705A (en) | 2020-05-31 |
| US20200270222A1 (en) | 2020-08-27 |
| AU2018346051A1 (en) | 2020-04-09 |
| FI3692023T3 (fi) | 2023-08-17 |
| KR102858188B1 (ko) | 2025-09-11 |
| AU2018346051B2 (en) | 2022-11-10 |
| EP3692023A4 (en) | 2021-04-07 |
| JP2023109868A (ja) | 2023-08-08 |
| PT3692023T (pt) | 2023-08-23 |
| JP2020536116A (ja) | 2020-12-10 |
| RU2020112784A3 (pl) | 2022-03-05 |
| JP7605898B2 (ja) | 2024-12-24 |
| RU2020112784A (ru) | 2021-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273705A (en) | Benzothiazole compounds and methods of using them for the treatment of neurodegenerative diseases | |
| EP3746135A4 (en) | METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE | |
| IL267082A (en) | Systems and methods for the treatment of neurological disorders | |
| IL275506A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| IL275562A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| ZA201900519B (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| IL281052A (en) | Treatment of liver disorders | |
| EP3250210A4 (en) | Compositions and methods for treating cns disorders | |
| IL289423B2 (en) | Compounds and methods for treating neurological and cardiovascular conditions | |
| EP3280420A4 (en) | Compositions and methods for treating cns disorders | |
| IL267818A (en) | Methods for treating neurological disorders | |
| IL262825A (en) | Tetrahydropyridine and tetrahydropyrimidine substances, preparations containing them and their use for pain treatment | |
| PL3579826T3 (pl) | Sposoby leczenia zaburzeń cdkl5 związkiem ov329 | |
| IL270114B1 (en) | Methods and compounds for the treatment of neurological diseases | |
| SG10201913400QA (en) | Methods for treating lung disorders | |
| ZA201800831B (en) | Compositions and methods for treating and preventing neurodegenerative disorders | |
| ZA202002993B (en) | Compounds for the treatment of neuromuscular disorders | |
| ZA201907975B (en) | Agent for preventing or treating tauopathy | |
| EP3313387A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| IL280424A (en) | Methods for treating neurodegenerative disorders | |
| EP3131635A4 (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
| HK40019969A (en) | Methods for treating neurodegenerative disorders | |
| HK40040286A (en) | Compositions and methods for treating cns disorders | |
| HK40055035A (en) | Treating liver disorders | |
| PT3724173T (pt) | Compostos para o tratamento de distúrbios neuromusculares |